These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25605815)

  • 1. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Horbinski C
    Neuro Oncol; 2015 Mar; 17(3):478-9. PubMed ID: 25605815
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas.
    Zou Y; Bai HX; Wang Z; Yang L
    Neuro Oncol; 2015 Mar; 17(3):477-8. PubMed ID: 25556921
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Chen L; Voronovich Z; Clark K; Hands I; Mannas J; Walsh M; Nikiforova MN; Durbin EB; Weiss H; Horbinski C
    Neuro Oncol; 2014 Nov; 16(11):1478-83. PubMed ID: 24860178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
    Kim H; Kim S; Lee HH; Heo H
    Korean J Radiol; 2016; 17(5):620-32. PubMed ID: 27587950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 6. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
    Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
    Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
    [No Abstract]   [Full Text] [Related]  

  • 7. Two Unique Glioma Subtypes Revealed.
    Poh A
    Cancer Discov; 2016 Apr; 6(4):334-5. PubMed ID: 26917670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
    Hirano M; Ohka F; Maeda S; Chalise L; Yamamichi A; Aoki K; Kato A; Tanahashi K; Motomura K; Nishimura Y; Hara M; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Brain Tumor Pathol; 2018 Apr; 35(2):97-105. PubMed ID: 29460200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From GWAS risk foci to glioma molecular subclass.
    Yung WK
    Neuro Oncol; 2013 May; 15(5):513-4. PubMed ID: 23620433
    [No Abstract]   [Full Text] [Related]  

  • 10. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
    Weller M; Wick W; von Deimling A
    Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Massive dissemination of adult glioblastomas.
    Willard N; Kleinschmidt-DeMasters BK
    Clin Neuropathol; 2015; 34(6):330-42. PubMed ID: 26308254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correspondence regarding: diagnostic utility of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009:68;1319-25.
    Wiwanitkit V
    J Neuropathol Exp Neurol; 2010 Mar; 69(3):320; author reply 320-1. PubMed ID: 20190607
    [No Abstract]   [Full Text] [Related]  

  • 15. IDH mutation status in prostate cancer.
    Ghiam AF; Cairns RA; Thoms J; Dal Pra A; Ahmed O; Meng A; Mak TW; Bristow RG
    Oncogene; 2012 Aug; 31(33):3826. PubMed ID: 22120718
    [No Abstract]   [Full Text] [Related]  

  • 16. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance metabolic imaging of glioma.
    Metellus P; Figarella-Branger D
    Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.